Información de Jazz Pharmaceuticals PLC, dividendo de Jazz Pharmaceuticals PLC, actividades de los accionistas y más

Más Datos de Jazz Pharmaceuticals PLC Compañía

Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).

Información de la empresa

Símbolo de cotizaciónJAZZ

Nombre de la empresaJazz Pharmaceuticals PLC

Fecha de salida a bolsaJan 18, 2012

Director ejecutivoMs. Renee D. Gala

Número de empleados2800

Tipo de seguridadOrdinary Share

Fin del año fiscalJan 18

DirecciónFifth Floor, Waterloo Exchange

CiudadDUBLIN

Bolsa de valoresNASDAQ Global Select Consolidated

PaísIreland

Código postal- -

Teléfono35316347800

Sitio Webhttps://www.jazzpharma.com/

Símbolo de cotizaciónJAZZ

Fecha de salida a bolsaJan 18, 2012

Director ejecutivoMs. Renee D. Gala

Ejecutivos de la empresa

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Seamus C. Mulligan

Independent Director

1.27M

+8.67%

Mr. Bruce C. Cozadd

Chairman of the Board

335.96K

-0.30%

Dr. Robert Iannone, M.D.

Executive Vice President, Global Head - Research and Development, Chief Medical Officer

31.28K

--

Ms. Renee D. Gala

President, Chief Executive Officer, Director

29.39K

--

Mr. Kenneth W. (Ken) O'Keefe

Independent Director

27.68K

--

Ms. Neena M. Patil, J.D.

Executive Vice President, Chief Legal Officer

21.63K

-15.90%

Mr. Philip L. Johnson

Chief Financial Officer, Executive Vice President

15.00K

--

Dr. Norbert G. Riedel, Ph.D.

Independent Director

12.22K

--

Ms. Anne O'Riordan

Independent Director

11.07K

--

Mr. Rick E. Winningham

Lead Independent Director

8.96K

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Seamus C. Mulligan

Independent Director

1.27M

+8.67%

Mr. Bruce C. Cozadd

Chairman of the Board

335.96K

-0.30%

Dr. Robert Iannone, M.D.

Executive Vice President, Global Head - Research and Development, Chief Medical Officer

31.28K

--

Ms. Renee D. Gala

President, Chief Executive Officer, Director

29.39K

--

Mr. Kenneth W. (Ken) O'Keefe

Independent Director

27.68K

--

Ms. Neena M. Patil, J.D.

Executive Vice President, Chief Legal Officer

21.63K

-15.90%

Desglose de ingresos

Divisa: USDActualizado: dom., 6 de jul

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

Xywav

344.80M

38.40%

Epidiolex/epidyolex

217.74M

24.25%

Rylaze

94.23M

10.50%

Zepzelca

63.03M

7.02%

High-sodium oxybate AG royalty revenue

48.95M

5.45%

Other

129.09M

14.38%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

797.95M

88.87%

Europe

83.61M

9.31%

All Others

16.29M

1.81%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Xywav

344.80M

38.40%

Epidiolex/epidyolex

217.74M

24.25%

Rylaze

94.23M

10.50%

Zepzelca

63.03M

7.02%

High-sodium oxybate AG royalty revenue

48.95M

5.45%

Other

129.09M

14.38%

Estadísticas de accionistas

Actualizado: mar., 22 de jul

Accionistas

Tipos de accionistas

Accionistas

Proporción

The Vanguard Group, Inc.

9.91%

BlackRock Institutional Trust Company, N.A.

8.61%

LSV Asset Management

4.08%

Dimensional Fund Advisors, L.P.

3.85%

State Street Global Advisors (US)

3.25%

Other

70.31%

Accionistas

Proporción

The Vanguard Group, Inc.

9.91%

BlackRock Institutional Trust Company, N.A.

8.61%

LSV Asset Management

4.08%

Dimensional Fund Advisors, L.P.

3.85%

State Street Global Advisors (US)

3.25%

Other

70.31%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

53.78%

Investment Advisor/Hedge Fund

31.14%

Hedge Fund

9.59%

Research Firm

3.30%

Individual Investor

3.06%

Pension Fund

2.14%

Bank and Trust

1.04%

Venture Capital

0.85%

Sovereign Wealth Fund

0.18%

Participación institucional

Actualizado: mar., 1 de jul

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q2

1196

63.65M

105.18%

-6.19M

2025Q1

1235

63.66M

105.15%

-6.35M

2024Q4

1202

62.66M

103.17%

-6.51M

2024Q3

1172

61.48M

99.60%

-6.16M

2024Q2

1167

61.28M

97.21%

-6.97M

2024Q1

1163

63.08M

101.15%

-2.43M

2023Q4

1156

61.76M

98.11%

-3.48M

2023Q3

1158

61.08M

96.76%

-4.05M

2023Q2

1197

61.00M

95.34%

-4.11M

2023Q1

1207

61.36M

96.91%

-3.79M

Actividad de los accionistas

Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

5.99M

9.91%

-18.47K

-0.31%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

5.21M

8.61%

-33.38K

-0.64%

Mar 31, 2025

LSV Asset Management

2.47M

4.08%

-64.88K

-2.56%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

2.33M

3.85%

+293.36K

+14.42%

Mar 31, 2025

State Street Global Advisors (US)

1.97M

3.25%

-2.23K

-0.11%

Mar 31, 2025

Capital World Investors

1.93M

3.19%

+4.45K

+0.23%

Mar 31, 2025

EcoR1 Capital, LLC

1.71M

2.82%

--

Mar 31, 2025

JP Morgan Asset Management

1.50M

2.48%

+71.69K

+5.01%

Mar 31, 2025

Columbia Threadneedle Investments (US)

1.35M

2.24%

-136.12K

-9.14%

Mar 31, 2025

Fuller & Thaler Asset Management Inc.

1.33M

2.2%

+391.66K

+41.69%

Mar 31, 2025

ETFs relacionados

Actualizado: sáb., 2 de ago

Nombre

Proporción

AdvisorShares Pure Cannabis ETF

5.57%

Cambria Cannabis ETF

4.57%

SPDR S&P Pharmaceuticals ETF

3.68%

iShares U.S. Pharmaceuticals ETF

3.29%

First Trust NASDAQ Pharmaceuticals ETF

2.98%

Invesco Pharmaceuticals ETF

2.62%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

2.61%

First Trust Health Care Alphadex Fund

1.87%

Tema Neuroscience and Mental Health ETF

1.86%

VictoryShares Small Cap Free Cash Flow ETF

1.71%

AdvisorShares Pure Cannabis ETF

Proporción5.57%

Cambria Cannabis ETF

Proporción4.57%

SPDR S&P Pharmaceuticals ETF

Proporción3.68%

iShares U.S. Pharmaceuticals ETF

Proporción3.29%

First Trust NASDAQ Pharmaceuticals ETF

Proporción2.98%

Invesco Pharmaceuticals ETF

Proporción2.62%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proporción2.61%

First Trust Health Care Alphadex Fund

Proporción1.87%

Tema Neuroscience and Mental Health ETF

Proporción1.86%

VictoryShares Small Cap Free Cash Flow ETF

Proporción1.71%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones

Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos

Jazz Pharmaceuticals PLC

116.610USD

Jazz Pharmaceuticals PLC

116.610

Descripción general

Compañía

Finanzas